Chennai, January 27th, 2026: Caplin Steriles Limited (Caplin), a Subsidiary Company of Caplin Point Laboratories Limited (BSE: CAPPL (524742), NSE: CAPLIPOINT), has been granted final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Methylprednisolone Acetate Injectable Suspension USP, 40mg/mL & 80mg/mL Single Dose vials, a generic therapeutic equivalent version of the Reference Listed Drug (RLD) DEPO-MEDROL from Pfizer Inc., USA.
Methylprednisolone Acetate Injectable Suspension is primarily used as an anti-inflammatory treatment in various conditions, including in allergic states, dermatologic diseases, endocrine disorders, gastrointestinal diseases, hematologic diseases, ophthalmic diseases, respiratory diseases, rheumatic disorders etc. According to IQVIATM (IMS Health), Methylprednisolone Acetate Injectable Suspension USP, 40mg/mL & 80mg/mL Single Dose vials had US sales of approximately $57.4 million for the 12-month period ending November 2025.